OverviewChartNewsTraderScreen

Morgan Stanley Call 102.5 NOVN 19.../  DE000MG2UXA3  /

Stuttgart
2024-11-12  9:19:28 PM Chg.- Bid9:57:12 AM Ask9:57:12 AM Underlying Strike price Expiration date Option type
0.260EUR - 0.260
Bid Size: 80,000		 0.270
Ask Size: 80,000		 NOVARTIS N 102.50 CHF 2025-12-19 Call
TeleTrader 10-29 Novartis' Q2 EPS surge by 116% to $1.58
GlobeNewswire 07-30 Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
TeleTrader 07-18 Novartis Q2 EPS up 47% to $1.60
GlobeNewswire 07-08 Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire 06-26 As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire 06-13 Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 05-13 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
TeleTrader 05-02 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 04-23 Novartis up 5% on upbeat guidance, earnings
TeleTrader 04-23 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 04-16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire 04-11 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 04-09 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 03-14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 02-28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire 02-28 PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B
TeleTrader 01-31 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 01-10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 01-05 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 01-02 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 2023-12-21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...